NCT03127761 Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
| NCT ID | NCT03127761 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Center for International Blood and Marrow Transplant Research |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 544 participants |
| Start Date | 2017-07-25 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 544 participants in total. It began in 2017-07-25 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.
Eligibility Criteria
Inclusion Criteria: * Medicare beneficiary * Stage II or III multiple myeloma and/or primary plasma cell leukemia * Eligible to receive an allogeneic HCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood * Will receive allogeneic HCT at a US transplant center * Agree to submit comprehensive clinical data on their pre- and post-transplant clinical status and outcomes to the CIBMTR
Contact & Investigator
Anita D'Souza, MD, MS
STUDY CHAIR
CIBMTR, Medical College of Wisconsin
Frequently Asked Questions
Who can join the NCT03127761 clinical trial?
This trial is open to participants of all sexes, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03127761 currently recruiting?
Yes, NCT03127761 is actively recruiting participants. Contact the research team at mopatel@mcw.edu for enrollment information.
Where is the NCT03127761 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT03127761 clinical trial?
NCT03127761 is sponsored by Center for International Blood and Marrow Transplant Research. The principal investigator is Anita D'Souza, MD, MS at CIBMTR, Medical College of Wisconsin. The trial plans to enroll 544 participants.